A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer

Table 3

Efficacy evaluation.

Parameter		2-weekly NDLS (n = 9) (%)	3-weekly NDLS (n = 15) (%)
PSA decline	PSA decline >50%	77.8%	60%
	PSA decline >90%	55.6%	40%
Median %PSA decline		96.31%	83.29%
Median TTF (days)		200	195
Therapy after NDLS treatment^∗	Abiraterone (n = 4)	1	3
	Biculatamide^∗∗ (n = 5)	0	5
	Cabazitaxel (n = 1)	1	0
	Cyclophosphamide (n = 1)	0	1
	Enzalutamide (n = 2)	1	1
	Mitoxantrone (n = 1)	0	1

NDLS = nanosomal docetaxel lipid suspension, PSA = prostate specific antigen; TTF, time-to-treatment failure. Details for therapy after NDLS treatment are available for 14 patients only. One patient received fosfesterol, and another patient received leuprolide along with bicalutamide who had received 3-weekly NDLS as second-line therapy.